Company Description
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer.
The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers.
It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University.
The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024.
Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jul 25, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Iain Dukes |
Contact Details
Address: 12 Penns Trail Newtown, Pennsylvania 18940 United States | |
| Phone | 267 759 3680 |
| Website | trawspharma.com |
Stock Details
| Ticker Symbol | TRAW |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001130598 |
| CUSIP Number | 68232V884 |
| ISIN Number | US68232V8845 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Iain D. Dukes DPHIL, M.A., Ph.D. | Chief Executive Officer, Secretary and Director |
| Dr. Nikolay Savchuk Ph.D. | Chief Operating Officer and Director |
| Dr. Charles David Pauza Ph.D. | Chief Scientific Officer of Virology |
| Charles Parker | Chief Financial Officer |
| Dr. Victor Mandia Moyo M.D. | Chief Medical Officer of Oncology |
| Dr. Robert R. Redfield M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 29, 2026 | ARS | Filing |
| May 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 29, 2026 | DEF 14A | Other definitive proxy statements |
| May 27, 2026 | 8-K | Current Report |
| May 26, 2026 | 8-K | Current Report |
| May 22, 2026 | 424B5 | Filing |
| May 19, 2026 | PRE 14A | Other preliminary proxy statements |
| May 15, 2026 | EFFECT | Notice of Effectiveness |
| May 15, 2026 | 424B3 | Prospectus |
| May 15, 2026 | SCHEDULE 13G/A | Filing |